Clinical study on the treatment of chronic atrophic gastritis with intestinal metaplasia using Moluodan combined with argon plasma coagulation

doi:10.3877/cma.j.issn.2095-2015.2026.05.012

Abstract

Abstract:

Objective

To investigate the clinical efficacy of Moluodan combined with argon plasma coagulation (APC) in the treatment of chronic atrophic gastritis (CAG) with intestinal metaplasia.

Methods

A retrospective study was conducted to collect clinical data of 119 patients with CAG accompanied by intestinal metaplasia admitted to XD Group Hospital from April 2024 to May 2025. They were divided into a control group (59 cases, treated with APC) and an observation group (60 cases, treated with APC+Moluodan) according to different treatment methods. The clinical efficacy, traditional Chinese medicine (TCM) syndrome scores, gastroscopy mucosal sign scores, gastrointestinal function indicators, and inflammatory factor levels were compared between the two groups. Adverse reactions were recorded.

Results

Compared with the control group, the observation group demonstrated a higher overall response rate [49 (83.05) vs. 57(95.00), P<0.05]. At 6 months of treatment, the observation group showed lower endoscopic mucosal sign scores and TCM syndrome scores than the control group (P<0.05). At 6 months of treatment, the observation group exhibited superior gastrointestinal function indicators and inflammatory cytokine levels compared to the control group (P<0.05). No significant differences were observed in adverse reactions between the two groups (P>0.05).

Conclusion

The combination of Moluodan and APC has a significant therapeutic effect on CAG with intestinal metaplasia. It can effectively alleviate clinical symptoms, promote mucosal repair, regulate gastrointestinal function, reduce inflammatory reactions, and has good safety.

Key words: Chronic atrophic gastritis, Intestinal metaplasia, Argon plasma coagulation, Moluodan, Gastrointestinal function

Yichen Wang, Huaili Xu, Wei Ju. Clinical study on the treatment of chronic atrophic gastritis with intestinal metaplasia using Moluodan combined with argon plasma coagulation[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2026, 16(05): 463-468.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2026.05.012

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2026/V16/I05/463

Figures/Tables 6

References 25

[1]	Morgan DR, Corral JE, Li D, et al. ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions[J]. Am J Gastroenterol, 2025, 120(4): 709-737.
[2]	Tziatzios G, Ziogas DΙ, Gkolfakis P, et al. Endoscopic Grading and Sampling of Gastric Precancerous Lesions: A Comprehensive Literature Review[J]. Curr Oncol, 2024, 31(7): 3923-3938.
[3]	Dilaghi E, Bellisario M, Esposito G, et al. The Impact of Proton Pump Inhibitors on the Development of Gastric Neoplastic Lesions in Patients With Autoimmune Atrophic Gastritis[J]. Front Immunol, 2022, 13(1): 910077.
[4]	Zhang T, Zhang B, Xu J, et al. Chinese herbal compound prescriptions combined with Chinese medicine powder based on traditional Chinese medicine syndrome differentiation for treatment of chronic atrophic gastritis with erosion: a multi-center, randomized, positive-controlled clinical tria[J]. Chin Med, 2022, 17(1): 142.
[5]	Sun Z, Deng H, Liu Y, et al. A Systematic Review and Meta-Analysis of Xiangsha Liujunzi Decoction in the Treatment of Chronic Gastritis[J]. Comb Chem High Throughput Screen, 2024, 27(3): 386-399.
[6]	黄禹, 陈希丽, 洪艾婧, 等. 荜铃胃痛颗粒联合摩罗丹治疗老年Hp阳性慢性萎缩性胃炎的疗效及对炎性因子和胃肠功能的影响[J]. 现代生物医学进展, 2025, 25(19): 3084-3090.
[7]	王伟民, 段晨超, 蔡晓阳. 摩罗丹辅助常规西药治疗慢性萎缩性胃炎的效果研究[J]. 中国实用医刊, 2025, 52(9): 118-120.
[8]	中华医学会消化病学分会, 中华医学会消化病学分会消化系统肿瘤协作组, 房静远. 中国慢性胃炎诊治指南(2022年,上海)[J]. 胃肠病学, 2023, 28(3): 149-180.
[9]	中国中西医结合学会消化系统疾病专业委员会. 慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J]. 中国中西医结合消化杂志, 2018, 26(2): 121-131.
[10]	Hwang YJ, Choi Y, Kim N, et al. The Difference of Endoscopic and Histologic Improvements of Atrophic Gastritis and Intestinal Metaplasia After Helicobacter pylori Eradication[J]. Dig Dis Sci, 2022, 67(7): 3055-3066.
[11]	Kligman E, Ali H, Chen E, et al. Ethnicity Is an Important Consideration in Screening for Gastric Intestinal Metaplasia[J]. Dig Dis Sci, 2022, 67(9): 4509-4517.
[12]	Zhang Y, Wang Y, Wang X, et al. Jianpi Fuzheng Xiaoji formula ameliorates gastric precancerous lesions via suppression of neutrophil extracellular trap formation[J]. J Ethnopharmacol, 2026, 364(1): 121459.
[13]	Zhang Y, Yang Q, Song B, et al. Efficacy and safety of Piwei Peiyuan Prescription in the treatment of chronic atrophic gastritis: A multicenter, double-blind, double-simulated, randomized, controlled clinical trial[J]. Medicine(Baltimore), 2024, 103(19): e37981.
[14]	Mai Z, Zheng Y, Xie J, et al. JianPi QingRe HuoXue Formula targets Cadherin-17 to induce apoptosis in chronic atrophic gastritis with intestinal metaplasia.[J]. Phytomedicine, 2026, 154(1): 158037.
[15]	潘菲. 胃镜下高频电切联合氩等离子体凝固术对消化道息肉患者术后疼痛及胃肠功能的影响[J]. 中国医学创新, 2022, 19(36): 33-36.
[16]	伍沁芳, 杨晓薇, 成诚. 摩罗丹+改良四联序贯疗法在Hp阳性慢性萎缩性胃炎中的应用效果[J]. 中国医学创新, 2025, 22(12): 9-13.
[17]	李华丽. 摩罗丹联合四联疗法治疗幽门螺杆菌阳性慢性萎缩性胃炎临床研究[J]. 新中医, 2024, 56(3): 33-38.
[18]	Cella CA, Ciardiello D, Gervaso L, et al. Role of the microbiome in the development and treatment of gastric cancer: an overview of the biological and clinical landscape[J]. ESMO Gastrointest Oncol, 2024, 4(1): 100048.
[19]	Wang X, Jiao J, Huh WJ, et al. Histopathologic Progression of Autoimmune Atrophic Gastritis: A Retrospective Review of 180 Specimens From 32 Patients[J]. Arch Pathol Lab Med, 2025, 150(1): 81-87.
[20]	Huang RJ, Park S, Shen J, et al. Pepsinogens and Gastrin Demonstrate Low Discrimination for Gastric Precancerous Lesions in a Multi-Ethnic United States Cohort[J]. Clin Gastroenterol Hepatol, 2022, 20(4): 950-952, e3.
[21]	Zhang Y, Feng Y, You C, et al. Relationship between Helicobacter pylori infection and different pathological types of chronic atrophic gastritis and analysis of serum gastric function[J]. J Infect Dev Ctries, 2025, 19(12): 1774-1779.
[22]	Hayashi J, Yamatsuji T, Suehiro M, et al. Helicobacter pylori-Negative Advanced Gastric Cancer Arising from the Gastric Mucosa without Inflammation, Atrophy, or Intestinal Metaplasia[J]. Case Rep Gastroenterol, 2022, 16(2): 345-350.
[23]	Wei W, Wang R, Zhu B, et al. Integrating network pharmacology, pharmacokinetics and experimental validation to reveal the potential mechanism of Physochlaina physaloides(L.)G. Don in chronic atrophic gastritis[J]. J Ethnopharmacol, 2026, 354(1): 120487.
[24]	黄春锦, 王艳富, 李冀. 基于网络药理学和分子对接探讨健脾清热方治疗慢性萎缩性胃炎伴肠上皮化生的作用机制[J]. 老年医学与保健, 2025, 31(2): 481-486.
[25]	Xue P. Serum level of(interleukin(IL)-2, IL-10, tumor necrosis factor(TNF)-a, motilin(MTL), gastrin(GAS), pepsinogen(PG), after adjunctive treatment in patients with chronic atrophic gastritis[J]. J Med Biochem, 2025, 44(7): 1505-1514.

组别	例数	男/女(例)	年龄(岁,±s)	体重指数(kg/m²,±s)	萎缩程度[例(%)]
组别	例数	男/女(例)	年龄(岁,±s)	体重指数(kg/m²,±s)	中度	重度
对照组	59	34/25	59.73±5.28	22.45±2.40	28(47.46)	31(52.54)
观察组	60	38/22	58.58±5.03	22.30±2.48	27(45.00)	33(55.00)
χ²/t值		0.405	1.217	0.335	0.072
P值		0.524	0.226	0.738	0.788
组别	例数	肠化程度[例(%)]		病变部位[例(%)]
组别	例数	轻度	中度	胃窦	胃体	多部位
对照组	59	38(64.41)	21(35.59)	34(57.63)	15(25.43)	10(16.94)
观察组	60	35(58.33)	25(41.67)	38(63.33)	12(20.00)	10(16.67)
χ²值		0.463		0.547
P值		0.496		0.761

组别	例数	男/女(例)	年龄(岁,±s)	体重指数(kg/m²,±s)	萎缩程度[例(%)]
组别	例数	男/女(例)	年龄(岁,±s)	体重指数(kg/m²,±s)	中度	重度
对照组	59	34/25	59.73±5.28	22.45±2.40	28(47.46)	31(52.54)
观察组	60	38/22	58.58±5.03	22.30±2.48	27(45.00)	33(55.00)
χ²/t值		0.405	1.217	0.335	0.072
P值		0.524	0.226	0.738	0.788
组别	例数	肠化程度[例(%)]		病变部位[例(%)]
组别	例数	轻度	中度	胃窦	胃体	多部位
对照组	59	38(64.41)	21(35.59)	34(57.63)	15(25.43)	10(16.94)
观察组	60	35(58.33)	25(41.67)	38(63.33)	12(20.00)	10(16.67)
χ²值		0.463		0.547
P值		0.496		0.761

组别	例数	临床疗效				总有效
组别	例数	临床痊愈	显效	有效	无效	总有效
对照组	59	10(16.95)	20(33.90)	19(32.20)	10(16.95)	49(83.05)
观察组	60	14(23.33)	22(36.67)	21(35.00)	3(5.00)	57(95.00)^a

组别	例数	临床疗效				总有效
组别	例数	临床痊愈	显效	有效	无效	总有效
对照组	59	10(16.95)	20(33.90)	19(32.20)	10(16.95)	49(83.05)
观察组	60	14(23.33)	22(36.67)	21(35.00)	3(5.00)	57(95.00)^a

组别	例数	中医证候评分		胃镜黏膜征象积分
组别	例数	治疗前	治疗6个月	治疗前	治疗6个月
对照组	59	10.32±2.25	7.68±2.10^a	12.44±2.41	9.34±1.98^a
观察组	60	10.50±2.18	5.23±1.84^a	12.27±2.36	6.75±2.04^a
t值		0.438	6.757	0.398	7.027
P值		0.662	<0.001	0.692	<0.001

Please choose a citation manager

Content to export